Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design

Rappuoli et al. illustrate how new breakthroughs in the field of human immunology can be combined with insights from structural and computational biology for the rational design of novel broadly protective immunogens, potentiating the development of new vaccines against infectious diseases that still present an important unmet medical need.

[1]  G. Fuh,et al.  Erratum: Endothelial exocytosis of angiopoietin-2 resulting from CCM3 deficiency contributes to cerebral cavernous malformation , 2016, Nature Medicine.

[2]  R. Rappuoli,et al.  Self-assembling protein nanoparticles in the design of vaccines , 2015, Computational and Structural Biotechnology Journal.

[3]  J. Mascola,et al.  Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection , 2015, Science Translational Medicine.

[4]  M. Bottomley,et al.  Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens , 2015, Journal of immunology research.

[5]  Ruedi Aebersold,et al.  Antigenic Characterization of the HCMV gH/gL/gO and Pentamer Cell Entry Complexes Reveals Binding Sites for Potently Neutralizing Human Antibodies , 2015, PLoS pathogens.

[6]  Adrian Apetri,et al.  A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen , 2015, Science.

[7]  J. Mascola,et al.  Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection , 2015, Nature Medicine.

[8]  B. Haynes.  New approaches to HIV vaccine development. , 2015, Current opinion in immunology.

[9]  George Georgiou,et al.  Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire. , 2015, Current opinion in immunology.

[10]  David Nemazee,et al.  Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen , 2015, Science.

[11]  G. Debnath,et al.  D-101 HIV-1 neutralizing antibodies induced by native-like envelope trimers , 2016 .

[12]  Michael S. Seaman,et al.  Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 , 2015, Nature.

[13]  Daniel W. Kulp,et al.  Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice , 2015, Cell.

[14]  John R Mascola,et al.  Antibody responses to envelope glycoproteins in HIV-1 infection , 2015, Nature Immunology.

[15]  M. Bottomley,et al.  Protein Crystallography in Vaccine Research and Development , 2015, International journal of molecular sciences.

[16]  E. De Gregorio,et al.  MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life , 2015, The Journal of Immunology.

[17]  Johannes Trück,et al.  Identification of Antigen-Specific B Cell Receptor Sequences Using Public Repertoire Analysis , 2015, The Journal of Immunology.

[18]  F. Sallusto,et al.  Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies , 2014, Proceedings of the National Academy of Sciences.

[19]  R. Rappuoli.  Vaccines: Science, health, longevity, and wealth , 2014, Proceedings of the National Academy of Sciences.

[20]  Mark M. Davis,et al.  Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. , 2014, Cell host & microbe.

[21]  Gwo-Yu Chuang,et al.  Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface , 2014, Nature.

[22]  Peter W Mason,et al.  Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. , 2014, Vaccine.

[23]  Chaim A. Schramm,et al.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.

[24]  David Baker,et al.  Proof of principle for epitope-focused vaccine design , 2014, Nature.

[25]  Andrew D. Ellington,et al.  Identification and characterization of the constituent human serum antibodies elicited by vaccination , 2014, Proceedings of the National Academy of Sciences.

[26]  J. Stoddard,et al.  A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program , 2013, Drugs.

[27]  Gira Bhabha,et al.  A common solution to group 2 influenza virus neutralization , 2013, Proceedings of the National Academy of Sciences.

[28]  M. Nussenzweig,et al.  Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia , 2013, Nature.

[29]  Cinque S. Soto,et al.  Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus , 2013, Science.

[30]  Michael S. Seaman,et al.  Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.

[31]  J. Mascola,et al.  Isolation of human monoclonal antibodies from peripheral blood B cells , 2013, Nature Protocols.

[32]  F. Baldanti,et al.  Cross-neutralization of four paramyxoviruses by a human monoclonal antibody , 2013, Nature.

[33]  Florian Klein,et al.  Antibodies in HIV-1 Vaccine Development and Therapy , 2013, Science.

[34]  J. Whittle,et al.  Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies , 2013, Nature.

[35]  Scott D Boyd,et al.  Convergent antibody signatures in human dengue. , 2013, Cell host & microbe.

[36]  U. Baxa,et al.  Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody , 2013, Science.

[37]  David Nemazee,et al.  Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.

[38]  P. Wilson,et al.  Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis. , 2013, Immunobiology.

[39]  Chaim A. Schramm,et al.  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.

[40]  J. McLellan,et al.  Structure and function of respiratory syncytial virus surface glycoproteins. , 2013, Current topics in microbiology and immunology.

[41]  R. Rappuoli,et al.  Structural vaccinology starts to deliver , 2012, Nature Reviews Microbiology.

[42]  N. S. Laursen,et al.  Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.

[43]  D. Baltimore,et al.  Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission , 2012, Retrovirology.

[44]  I. Wilson,et al.  A Virus-Like Particle That Elicits Cross-Reactive Antibodies to the Conserved Stem of Influenza Virus Hemagglutinin , 2012, Journal of Virology.

[45]  R. Rappuoli,et al.  The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. , 2012, Vaccine.

[46]  Thomas B Kepler,et al.  B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study , 2012, Nature Biotechnology.

[47]  M. Diamond,et al.  Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions , 2012, Proceedings of the National Academy of Sciences.

[48]  R. Albrecht,et al.  Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes , 2012, Journal of Virology.

[49]  C. Palomo,et al.  Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention , 2012, Proceedings of the National Academy of Sciences.

[50]  David Baltimore,et al.  Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxis , 2011, Nature.

[51]  J. Stockman.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis , 2012 .

[52]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[53]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[54]  J. Crowe,et al.  A Broadly Neutralizing Human Monoclonal Antibody That Recognizes a Conserved, Novel Epitope on the Globular Head of the Influenza H1N1 Virus Hemagglutinin , 2011, Journal of Virology.

[55]  Martin H. Koldijk,et al.  A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.

[56]  J. Skehel,et al.  A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.

[57]  S. Reddy,et al.  Systems analysis of adaptive immunity by utilization of high-throughput technologies. , 2011, Current opinion in biotechnology.

[58]  W. Schief,et al.  Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. , 2011, Journal of molecular biology.

[59]  F. Sallusto,et al.  High throughput cellular screens to interrogate the human T and B cell repertoires. , 2011, Current opinion in immunology.

[60]  C. Mandl,et al.  Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers , 2011, Proceedings of the National Academy of Sciences.

[61]  Michael Meyer-Hermann,et al.  Germinal Center Dynamics Revealed by Multiphoton Microscopy with a Photoactivatable Fluorescent Reporter , 2010, Cell.

[62]  Maxim N. Artyomov,et al.  Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation , 2010, Nature.

[63]  Cameron P Simmons,et al.  The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. , 2010, Cell host & microbe.

[64]  P. Lipsky,et al.  Secondary Immunization Generates Clonally Related Antigen-Specific Plasma Cells and Memory B Cells , 2010, The Journal of Immunology.

[65]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[66]  K. Subbarao,et al.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. , 2010, The Journal of clinical investigation.

[67]  S. Madhi,et al.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis , 2010, The Lancet.

[68]  J. Langley,et al.  Prospects for defined epitope vaccines for respiratory syncytial virus. , 2010, Future microbiology.

[69]  P. Kwong,et al.  Structural basis of respiratory syncytial virus neutralization by motavizumab , 2010, Nature Structural &Molecular Biology.

[70]  Andreas Radbruch,et al.  Generation of stable monoclonal antibody-producing BCR+ human memory B cells by genetic programming , 2009, Nature Medicine.

[71]  Antonio Lanzavecchia,et al.  Isolation of Human Monoclonal Antibodies That Potently Neutralize Human Cytomegalovirus Infection by Targeting Different Epitopes on the gH/gL/UL128-131A Complex , 2009, Journal of Virology.

[72]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[73]  D. Dimitrov,et al.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens , 2009, Biochemical and Biophysical Research Communications.

[74]  M. Connors,et al.  Antibody-secreting B cells in HIV infection , 2009, Current opinion in HIV and AIDS.

[75]  Hiroyuki Kishi,et al.  A rapid and efficient single-cell manipulation method for screening antigen-specific antibody–secreting cells from human peripheral blood , 2009, Nature Medicine.

[76]  F. Pereyra,et al.  A method for identification of HIV gp140 binding memory B cells in human blood. , 2009, Journal of immunological methods.

[77]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[78]  Richard T. Wyatt,et al.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.

[79]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[80]  I. Stephenson,et al.  Influenza vaccines for the future , 2009 .

[81]  Y. Guan,et al.  Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells , 2008, PloS one.

[82]  Rino Rappuoli,et al.  Structure-based antigen design: a strategy for next generation vaccines , 2008, Trends in Biotechnology.

[83]  Patrick C. Wilson,et al.  Rapid cloning of high-affinity human monoclonal antibodies against influenza virus , 2008, Nature.

[84]  John Steel,et al.  Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies , 2008, Proceedings of the National Academy of Sciences.

[85]  Michel C Nussenzweig,et al.  Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.

[86]  S. Khuder,et al.  Immune Response to Pneumococcal Polysaccharides 4 and 14 in Elderly and Young Adults: Analysis of the Variable Heavy Chain Repertoire , 2005, Infection and Immunity.

[87]  E. Walsh,et al.  Respiratory syncytial virus infection in elderly and high-risk adults. , 2005, The New England journal of medicine.

[88]  Renate Kunert,et al.  Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. , 2005, Immunity.

[89]  Renate Kunert,et al.  Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.

[90]  B. Murphy,et al.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.

[91]  M. Nussenzweig,et al.  Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.

[92]  Rino Rappuoli,et al.  Reverse vaccinology. , 2000, Current opinion in microbiology.

[93]  D. Burton.  Antibodies, viruses and vaccines , 2002, Nature Reviews Immunology.

[94]  J. Venter,et al.  Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. , 2000, Science.

[95]  R. Rappuoli.  Reverse vaccinology : Genomics , 2000 .

[96]  H. Katinger,et al.  Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. , 1999, Immunity.

[97]  D. Baxby,et al.  Edward Jenner's Inquiry; a bicentenary analysis. , 1999, Vaccine.

[98]  Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. , 1998, Pediatrics.

[99]  N. J. Willis.  Edward Jenner and the Eradication of Smallpox , 1997, Scottish medical journal.

[100]  J. Schrader,et al.  A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[101]  R. Fleischmann,et al.  Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. , 1995, Science.

[102]  D R Burton,et al.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.

[103]  E. Emini,et al.  Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[104]  D R Burton,et al.  A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. , 1991, Proceedings of the National Academy of Sciences of the United States of America.